Compare · AZN vs LGVN
AZN vs LGVN
Side-by-side comparison of AstraZeneca PLC (AZN) and Longeveron Inc. (LGVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and LGVN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 12135.6x LGVN ($21.7M).
- LGVN has been more active in the news (24 items in the past 4 weeks vs 15 for AZN).
- AZN has more recent analyst coverage (25 ratings vs 2 for LGVN).
- Company
- AstraZeneca PLC
- Longeveron Inc.
- Price
- -
- -
- Market cap
- $263.10B
- $21.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 15
- 24
- Recent ratings
- 25
- 2
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Latest AZN
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
Latest LGVN
- Chief Financial Officer Jhaveri Nirav S. was granted 300,000 shares (SEC Form 4)
- New insider Jhaveri Nirav S. claimed no ownership of stock in the company (SEC Form 3)
- Longeveron Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Longeveron Announces 1-for-10 Reverse Stock Split
- Chief Medical Officer Agafonova Nataliya was granted 286,000 shares, increasing direct ownership by 66% to 716,914 units (SEC Form 4)
- CTO & SVP of CMC Blass Devin was granted 286,000 shares, increasing direct ownership by 67% to 711,735 units (SEC Form 4)
- Chief Scientific Officer Hare Joshua was granted 286,000 shares, increasing direct ownership by 22% to 1,607,796 units (SEC Form 4)
- Director Ascheim Deborah was granted 36,000 shares (SEC Form 4)
- Director Cann Leah Rush was granted 36,000 shares (SEC Form 4)
- Director Soffer Rock was granted 36,000 shares, increasing direct ownership by 16% to 262,034 units (SEC Form 4)